ABT-737

Ligand id: 8320

Name: ABT-737

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 8
Hydrogen bond donors 2
Rotatable bonds 17
Topological polar surface area 161.81
Molecular weight 812.26
XLogP 11.14
No. Lipinski's rules broken 2

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
ABT-737 has been assessed in a Phase II clinical trial investigating its effects on ex vivo ovarian cancer samples from patients [4-5,7].
Mechanism Of Action and Pharmacodynamic Effects
BH3 antagonists hinder the interaction between antiapoptotic and proapoptotic Bcl-2 proteins which is dysregulated in cancers overexpressing antiapoptotic proteins [3]. Such antagonists should restore the activity of proapoptotic proteins, thereby leading to tumour cell death. They may even help overcome resistance to chemotherapy which is a common feature of Bcl-2-overexpressing cancers [1].